Bartoli E, Sorrentino D, Trevisi A
Cattedra di Medicina Interna, Università degli Studi di Udine.
Ann Ital Med Int. 1997 Apr-Jun;12(2):98-102.
Randomized clinical trials represent the final, essential link between basic medical research and human health. However, their conduction presents very complex ethical problems, since the patient is the actual target of the experiment. Proper randomization, informed consent, and preliminary disclosure of results create deep ethical conflicts between the role of caretaker and that of impartial observer, both played by the same doctor. The dilemma reproduces the conflict between two different ethics. One is based on the inalienable individual rights stemming from the concept of man as an end in himself and not a means to an end. The other, derived from utilitarian philosophies, is based on the benefit for society as a whole. If we agree that randomized clinical trials represent the best method to test the validity of a new treatment, there is no easy solution. The dilemma could be solved by separating the role of the family doctor, committed to the best treatment possible for his patient, from the role of the scientist, committed to the progress of science and humanity. The former is involved in the treatment of individual patients, the latter in clinical and scientific experiments of a therapeutic nature. The patient may trade his rights to the best possible cure for the safety and the efficiency guaranteed by the scientific institution conducting the trial. Trials on relevant issues--expected to produce important results and impeccably designed scientifically--could be endowed with the ethics of science per se and this could be considered equivalent to the individual rights waived by the patient.
随机临床试验是基础医学研究与人类健康之间最终的、必不可少的环节。然而,其实施存在非常复杂的伦理问题,因为患者是实验的实际对象。恰当的随机分组、知情同意以及结果的提前披露,在由同一位医生扮演的照顾者角色与公正观察者角色之间产生了深刻的伦理冲突。这一两难困境再现了两种不同伦理之间的冲突。一种伦理基于人作为目的而非手段这一概念所衍生的不可剥夺的个人权利。另一种伦理源自功利主义哲学,基于对整个社会的益处。如果我们认同随机临床试验是检验新治疗方法有效性的最佳方式,那么就没有简单的解决办法。通过将致力于为其患者提供最佳治疗的家庭医生角色,与致力于科学和人类进步的科学家角色分开,或许可以解决这一两难困境。前者参与个体患者的治疗,后者参与具有治疗性质的临床和科学实验。患者可以用其获得最佳治疗的权利,来换取进行试验的科研机构所保证的安全性和有效性。针对有望产生重要结果且设计科学无懈可击的相关问题进行的试验,可以赋予其本身的科学伦理,并且这可以被视为等同于患者放弃的个人权利。